- Home
- SGMT vs PROK Comparison
SGMT vs PROK Comparison
Compare SGMT & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- PROK
- Stock Information
- Founded
- SGMT 2006
- PROK 2015
- Country
- SGMT United States
- PROK United States
- Employees
- SGMT N/A
- PROK N/A
- Industry
- SGMT
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGMT
- PROK Health Care
- Exchange
- SGMT Nasdaq
- PROK Nasdaq
- Market Cap
- SGMT 128.5M
- PROK 126.8M
- IPO Year
- SGMT 2023
- PROK N/A
- Fundamental
- Price
- SGMT $3.72
- PROK $0.91
- Analyst Decision
- SGMT Strong Buy
- PROK Buy
- Analyst Count
- SGMT 6
- PROK 4
- Target Price
- SGMT $25.67
- PROK $5.00
- AVG Volume (30 Days)
- SGMT 315.0K
- PROK 559.6K
- Earning Date
- SGMT 03-12-2025
- PROK 03-17-2025
- Dividend Yield
- SGMT N/A
- PROK N/A
- EPS Growth
- SGMT N/A
- PROK N/A
- EPS
- SGMT N/A
- PROK N/A
- Revenue
- SGMT N/A
- PROK $76,000.00
- Revenue This Year
- SGMT N/A
- PROK N/A
- Revenue Next Year
- SGMT N/A
- PROK N/A
- P/E Ratio
- SGMT N/A
- PROK N/A
- Revenue Growth
- SGMT N/A
- PROK N/A
- 52 Week Low
- SGMT $2.39
- PROK $0.87
- 52 Week High
- SGMT $7.38
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- SGMT 44.81
- PROK 32.38
- Support Level
- SGMT $3.70
- PROK $0.87
- Resistance Level
- SGMT $4.24
- PROK $1.06
- Average True Range (ATR)
- SGMT 0.23
- PROK 0.10
- MACD
- SGMT 0.04
- PROK 0.01
- Stochastic Oscillator
- SGMT 45.70
- PROK 21.95
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.